Results 131 to 140 of about 4,214 (170)
Some of the next articles are maybe not open access.
Proteasomes and immunoproteasomes.
Rivista di biologia, 2011In eukaryotic cells, the protein degradation is a highly regulated and selective process. Membrane-associated or extracellular proteins are degraded in lysosomes, whereas intracellular protein dismantling is primarily non-lysosomal, being realized by complex, not-membrane enclosed and energy-dependent effectors, the proteasomes, localized in both ...
Fietta, Pieranna, Delsante, Giovanni
openaire +2 more sources
On the role of the immunoproteasome in transplant rejection [PDF]
Immunogenetics, 2018 The immunoproteasome is expressed in cells of hematopoietic origin and is induced during inflammation by IFN-γ. Targeting the immunoproteasome with selective inhibitors has been shown to be therapeutically effective in pre-clinical models for autoimmune diseases, colitis-associated cancer formation, and transplantation.
Michael Basler +2 more
exaly +4 more sources
Targeting immunoproteasome in neurodegeneration: A glance to the future
Pharmacology & Therapeutics, 2023The immunoproteasome is a specialized form of proteasome equipped with modified catalytic subunits that was initially discovered to play a pivotal role in MHC class I antigen processing and immune system modulation. However, over the last years, this proteolytic complex has been uncovered to serve additional functions unrelated to antigen presentation.
Tundo G. R. +11 more
openaire +3 more sources
American Journal of Transplantation, 2017
Modern treatment strategies for the maintenance of allograft acceptance frequently target ubiquitously-expressed pathways, leading to significant side-effects and poor long-term allograft outcomes. Constitutive proteasome inhibitors, which have recently been introduced for the treatment of antibody-mediated rejection, target the ubiquitously-expressed ...
Eskandari, S. K. +3 more
openaire +1 more source
Modern treatment strategies for the maintenance of allograft acceptance frequently target ubiquitously-expressed pathways, leading to significant side-effects and poor long-term allograft outcomes. Constitutive proteasome inhibitors, which have recently been introduced for the treatment of antibody-mediated rejection, target the ubiquitously-expressed ...
Eskandari, S. K. +3 more
openaire +1 more source
A patent review of immunoproteasome inhibitors
Expert Opinion on Therapeutic Patents, 2018The ubiquitin-proteasome system is responsible for maintaining protein homeostasis and regulating a variety of cellular processes. The constitutive proteasome is expressed in all cells while the immunoproteasome (IP) is predominantly found in cells of hematopoietic origin.
Eva, Ogorevc +3 more
openaire +2 more sources
Immunoproteasome responds to injury in the retina and brain [PDF]
Journal of Neurochemistry, 2008 AbstractIt is well known that immunoproteasome generates peptides for MHC Class I occupancy and recognition by cytotoxic T lymphocytes (CTL). The present study focused on evidence for alternative roles for immunoproteasome. Retina and brain were analyzed for expression of immunoproteasome subunits using immunohistochemistry and western blotting under ...
Deborah A Ferrington +2 more
exaly +3 more sources
The Immunoproteasome: An Emerging Therapeutic Target
Current Topics in Medicinal Chemistry, 2011The proteasome, a large multisubunit protease complex, has been extensively investigated over the years, greatly enhancing our understanding of critical roles that the proteasome plays in cells. The FDA approval of bortezomib for the treatment of multiple myeloma and mantle cell lymphoma has validated the proteasome as an anticancer target.
Wooin, Lee, Kyung Bo, Kim
openaire +2 more sources
Development of isoquinolinone derivatives as immunoproteasome inhibitors
Bioorganic & Medicinal Chemistry Letters, 2022The inhibition of immunoproteasome is considered nowadays a promising strategy for the treatment of hematologic malignancies. In this paper we report the design, synthesis, and biological evaluation as immunoproteasome inhibitors of a new series of isoquinolinone derivatives characterized by a (E)-prop-1-ene fragment that connects the heterocycle to a ...
Ettari R. +5 more
openaire +3 more sources
Immunoproteasome as a Target for Prodrugs
Journal of Medicinal ChemistryImmunoproteasome (iCP) is a proteasome isoform that is expressed under inflammatory conditions such as cytokine interferon-γ exposure. The iCP has different catalytic subunits other than the standard CP (standard core particle), allowing the production of major histocompatibility complex class I (MHC-I) compatible peptides for eventual T-cell ...
Christine S. Muli +2 more
openaire +2 more sources
Immunoproteasomal Processing of Isolevuglandin Adducts in Hypertension
2023SUMMARY Abstract Figure Graphical Abstract Isolevuglandins (isoLGs) are lipid aldehydes that form in the presence of reactive oxygen species (ROS) and drive immune activation.
Néstor de la Visitación +10 more
openaire +2 more sources